Administrative Core

行政核心

• 批准号: 9752961
• 负责人: Haifa Shen
• 金额: $ 63.37万
• 依托单位: METHODIST HOSPITAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9752961
• 关键词: Administrator; Advisory Committees; Biological; Budgets; Cancer Biology; Cancer Center; Cancer Immunology Science; Cancer Model; Cells; Clinical Cancer Center; Communication; Communities; Consultations; Data; Dendritic Cell Vaccine; Dendritic Cells; Direct Costs; Education and Outreach; Ensure; Evaluation; Faculty; Funding; Future; Goals; Immune; Immune response; Immunotherapeutic agent; Infrastructure; Institution; Intellectual Property; Leadership; Malignant Neoplasms; Malignant neoplasm of pancreas; Medical center; Methodist Church; Modeling; National Cancer Institute; Nutrient; Pancreatic Ductal Adenocarcinoma; Patients; Performance; Pharmaceutical Preparations; Pilot Projects; Principal Investigator; Property; Research; Research Institute; Research Personnel; Research Project Grants; Resource Sharing; Resources; Scientist; Students; Teacher Professional Development; Technology; Technology Transfer; Texas; Training and Education; United States National Institutes of Health; Universities; University of Texas M D Anderson Cancer Center; Vaccination; Wages; Work; breast cancer vaccine; cancer immunotherapy; clinical translation; conflict resolution; data management; design; effector T cell; imaging capabilities; immunogenic; immunogenicity; improved; malignant breast neoplasm; meetings; member; oncology; physical property; physical science; programs; recruit; tumor microenvironment; tumor progression

ADMINISTRATIVE CORE – SUMMARY The proposed Center for Immunotherapeutic Transport Oncophysics (CITO) is focused on identifying and understanding the multi-scale transport properties of immune cells and molecules, both systemically and within the tumor microenvironment, and other specific biological and physical properties of the tumor microenvironment, to ultimately develop effective cancer immunotherapies. The major CITO components are summarized as follows. Project 1 proposes to determine the transport phenomena of dendritic cell (DC) vaccines for breast and pancreatic cancers and post-vaccination changes in the transport of endogenous DCs, effector T cells, and macromolecular drugs. This information will be used to improve immune responses in these two cancer models. Project 2 seeks to determine the effects of multi-scale transport phenomena of pancreatic ductal adenocarcinoma (PDAC) on the distribution of immune cells and nutrients in the tumor microenvironment, during tumor progression. The Transport Oncophysics Core (TOC) will support both projects with modeling, computational, and imaging capabilities to integrate the scientific data into parameters that ultimately inform the rational design of optimal cancer immunotherapeutics and to improve the immunogenicity of breast and pancreatic cancers, both of which are historically known to be lowly immunogenic. The Education and Outreach Unit (EOU) will serve as the communication and engagement platform for students, trainees, junior faculty investigators, and researchers of the CITO, and those of the Physical Sciences-Oncology Network (PS-ON) and beyond. The Administrative Core (AC) will be established as part of the CITO infrastructure through which the Principal Investigator (PI), Project Co-Leaders and Core Leader, researchers, trainees, advisors, NCI PS-ON program staff, and other scientific and patient communities can share information and synergize CITO-related activities. The AC will facilitate the accomplishment and evaluation of progress and the creation of a collaborative network for current and future scientists in physical sciences oncology. The AC will also oversee and manage the selection and funding of Pilot and Trans-Network Projects, coordinate the use of shared resources and facilities, and promote interaction with other PS-ON investigators. Dr. Mauro Ferrari (Center PI, senior physical sciences investigator, AC Co-Leader, TOC Leader; Houston Methodist Research Institute, HMRI) will serve as the AC Co-Leader (10% effort). Dr. Elizabeth Mittendorf (Center cancer clinical translation investigator; AC Co-Leader; Project 1 Co-Leader; MD Anderson Cancer Center), Dr. Rongfu Wang (Center senior cancer immunology investigator; AC Co-Leader; Project 1 Co-Leader; HMRI), and Dr. Rolf Brekken (senior cancer biology investigator; AC Co- Leader; Project 2 Co-Leader; UT Southwestern Medical Center) will also serve as the other three AC Co- Leaders (5% effort each in the AC). They will be supported by a Center Administrator and staff.

行政核心--摘要 拟议的免疫治疗运输肿瘤物理中心(CITO)的重点是识别和 了解免疫细胞和分子的多尺度运输特性，包括系统和 在肿瘤微环境内，以及肿瘤的其他特定生物和物理特性 微环境，以最终开发有效的癌症免疫疗法。CITO的主要组成部分 总结如下。项目1建议确定树突状细胞(DC)的转运现象 乳腺癌和胰腺癌疫苗以及接种后内源性DC运输的变化， 效应性T细胞和大分子药物。这些信息将被用来改善免疫反应 这两个癌症模型。项目2试图确定多尺度输送现象的影响。 胰腺导管腺癌(PDAC)对肿瘤内免疫细胞和营养物质分布的影响 肿瘤进展过程中的微环境。运输本体物理核心(TOC)将同时支持这两项 具有将科学数据集成到参数中的建模、计算和成像能力的项目 这最终为合理设计最佳的癌症免疫疗法提供了信息，并改善了 乳腺癌和胰腺癌的免疫原性，这两种癌症历史上都被认为是低免疫原性 免疫原性。教育和外展股(EOU)将充当沟通和接触的角色 为CITO的学生、学员、初级教研员和研究人员提供的平台，以及 物理科学-肿瘤学网络(PS-ON)及更多。将建立行政核心(AC) 作为CITO基础设施的一部分，首席调查员(PI)、项目共同负责人和核心 领导者、研究人员、实习生、顾问、NCI PS-On计划工作人员以及其他科学和患者 社区可以分享信息并协同开展与CITO相关的活动。咨询委员会将协助 完成和评估进展情况，并为当前和未来建立协作网络 自然科学和肿瘤学的科学家。咨询委员会还将监督和管理以下项目的遴选和拨款 试点和跨网络项目，协调使用共享资源和设施，促进 与其他PS-ON调查人员的互动。毛罗·费拉里博士(圆周率中心，高级物理科学研究员， AC联席负责人、TOC负责人；休斯顿卫理公会研究院(HMRI)将担任AC联席负责人 (10%努力)。伊丽莎白·米滕多夫博士(癌症临床翻译研究员；AC联合负责人；项目1 安德森癌症中心联合领导)，王荣福博士(中心癌症免疫学高级研究员； AC联合负责人；项目1联合负责人；HMRI)和Rolf Brekken博士(高级癌症生物学研究员；AC联合 领导者；项目2联合领导者；德克萨斯大学西南医学中心)也将作为其他三个AC联合- 领导者(AC中各5%的努力)。他们将由一名中心管理员和工作人员提供支持。